Probiotics may help some people with GERD symptoms, but they are not an established treatment for GERD and should not replace standard therapy.
Recent studies are more encouraging than older research. Some randomized trials found better symptom control when specific probiotics were used together with proton pump inhibitors (PPIs). However, improvements in symptoms have been more consistent than improvements in objective outcomes such as esophageal healing or acid exposure.
Current GERD guidelines do not recommend probiotics as a standard treatment.
Do probiotics help GERD?
Possibly, but the evidence is still limited.
Studies published through 2026 suggest that some probiotic products may reduce reflux-related symptoms, improve other digestive symptoms, or help maintain symptom control after PPI treatment.
The main limitation is that the stronger recent studies used probiotics with PPIs, rather than as standalone treatment. Research has also not clearly shown that probiotics improve objective signs of GERD, such as esophageal healing or acid exposure.
For now, probiotics are better viewed as a possible add-on treatment than as a treatment for GERD on their own.
What does the research show?
What the 2020 systematic review found
Earlier studies found some improvement in reflux-related symptoms, particularly regurgitation, but the results were inconsistent. In the 2020 systematic review, five of the 11 positive study comparisons reported benefits for reflux symptoms, while others reported improvements in dyspepsia, nausea, abdominal pain, or gas-related symptoms. The often-cited “79%” figure refers to the proportion of study comparisons that reported at least one positive outcome — not the percentage of patients who improved.
More recent randomized trials give a clearer picture because they specifically enrolled people with reflux esophagitis or GERD.
2024 trial: MH-02 plus rabeprazole
A 2024 randomized controlled trial included 110 people with reflux esophagitis.
Everyone received the PPI rabeprazole for eight weeks, together with either Bifidobacterium animalis subsp. lactis MH-02 or placebo.
The probiotic group had faster symptom relief during the first two weeks and better scores for some broader digestive symptoms. However, several important outcomes were not significantly better with the probiotic, including reflux symptom scores after eight weeks, overall cure rates, and endoscopic healing.
More than 90% of patients in both groups had mucosal healing.
The probiotic group also went longer before symptoms returned during follow-up. Overall, the study suggests that MH-02 may provide additional symptom benefits when used with a PPI, but it does not show that the probiotic can treat reflux esophagitis by itself.
2026 trial: multi-strain probiotic plus rabeprazole
A 2026 randomized controlled trial included 120 adults with GERD.
All participants took rabeprazole for the first eight weeks. They also received either placebo or a probiotic containing Lacticaseibacillus paracasei Zhang, Lactiplantibacillus plantarum P9, and Bifidobacterium animalis subsp. lactis V9.
After eight weeks, rabeprazole was stopped while probiotic or placebo treatment continued for another four weeks.
At week 12, the probiotic group had lower reflux symptom scores. This suggests that the probiotic may have helped maintain symptom control after PPI treatment ended.
However, all patients received a PPI first, so the trial does not show how well the probiotic would work as a standalone treatment. It also did not provide clear evidence of improved esophageal healing: only a small number of participants had follow-up endoscopy, and the difference between groups was not statistically significant.
Overall, the study strengthens the evidence for symptom improvement, but not for replacing standard GERD treatment.
Which probiotic strains have been studied?
Earlier strains such as LG21, YIT 10347, and HN019 were studied mainly for upper-GI or functional digestive symptoms rather than confirmed GERD. Some studies reported improvements in symptoms such as regurgitation or dyspepsia, but the evidence is not strong enough to show that these strains treat GERD.
Bifidobacterium animalis subsp. lactis MH-02
MH-02 has more directly relevant evidence.
In a 2024 randomized trial, it was used with rabeprazole in people with reflux esophagitis. It improved early symptom relief and some broader gastrointestinal symptoms but did not significantly improve esophageal healing.
The evidence therefore suggests that MH-02 may offer additional symptom benefits when used alongside a PPI, but it has not been shown to replace standard GERD treatment.
Multi-strain Lihuo probiotic
A 2026 randomized trial used a combination of L. paracasei Zhang, L. plantarum P9, and B. animalis subsp. lactis V9.
The probiotic group had better reflux symptom scores after 12 weeks. This finding applies to this specific formulation and treatment protocol and cannot automatically be generalized to other multi-strain probiotics.
How might probiotics affect reflux symptoms?
Researchers have proposed several mechanisms, including effects on the gut microbiome, GI motility, microbial metabolism, and immune signaling.
The 2026 trial found changes in gut bacteria and certain metabolites after probiotic treatment. These findings show that the intervention affected the intestinal microbiome, but they do not prove that those changes caused the improvement in reflux symptoms.
It would also be too strong to say that probiotics prevent acid reflux, strengthen the esophagus, reduce acid exposure, or speed up gastric emptying. These effects have not been clearly demonstrated in people with GERD.
For now, these mechanisms remain possible explanations rather than established effects.
Is there a recommended probiotic dose for GERD?
Major GERD guidelines do not currently recommend a specific probiotic strain, dose, or treatment duration for GERD.
Studies have used different strains, combinations, doses, and treatment periods, so the amounts used in individual trials should not be treated as standard GERD doses.
Even probiotics containing the same bacterial species may use different strains, which means results from one product cannot automatically be applied to another.
Probiotic supplements vs fermented foods
A probiotic product tested in a clinical trial is not equivalent to yogurt, kefir, kimchi, or sauerkraut.
According to an ISAPP consensus statement, fermented foods do not automatically qualify as probiotic foods. Some may not contain live microorganisms when consumed, and the microbes they contain may differ from the specific strains tested in clinical trials.
This means findings for MH-02 or another studied probiotic formulation cannot automatically be applied to fermented foods.
Are probiotics safe for people with GERD?
Probiotics are generally well tolerated by healthy adults. Mild side effects can include gas, bloating, or temporary digestive discomfort.
The NCCIH probiotic safety overview notes that probiotics have a long history of apparently safe use in healthy people, although long-term safety data remain limited for many products.
More caution is needed in people who are seriously ill, hospitalized, immunocompromised, or otherwise at higher risk of infection. Rare infections linked to probiotic organisms have been reported in vulnerable patients.
Product quality can also vary between supplements, including the strains and amounts they contain.
Probiotics should not delay medical evaluation of persistent or concerning reflux symptoms.
Can probiotics replace GERD medication?
Current evidence does not support replacing standard GERD treatment with probiotics.
The 2025 ASGE guideline recommends lifestyle measures and established treatments such as proton pump inhibitors (PPIs) for GERD. Probiotics are not included as standard therapy.
This is important when interpreting recent research: the strongest newer trials tested probiotics alongside PPI treatment. A benefit from adding a probiotic does not mean that it can replace the PPI.
Why is the evidence still limited?
The main problem is that the studies are difficult to compare.
Different probiotics were tested. Results from one strain or formulation may not apply to another.
Not all studies included people with confirmed GERD. Some involved healthy participants or people with other digestive disorders.
Symptom relief is not the same as objective improvement. Less heartburn does not necessarily mean less acid exposure or better healing of the esophagus.
Most recent trials tested probiotics alongside PPIs. This makes it difficult to measure the probiotic’s effect on its own.
Studies are still relatively small and short. Recent trials included about 100–120 participants and followed them for weeks or months.
Independent confirmation is limited. Positive findings from specific probiotic products still need to be reproduced in other studies.
When reflux symptoms need medical evaluation
According to NIDDK guidance on GERD, medical evaluation is important if reflux symptoms are persistent or occur with warning signs such as:
- difficulty or pain with swallowing;
- persistent vomiting;
- unexplained weight loss;
- vomiting blood;
- black or tarry stools;
- other signs of gastrointestinal bleeding.
Chest pain should not automatically be assumed to be GERD, since heart and other conditions can cause similar symptoms. New, severe, or unexplained chest pain should be medically assessed.
Bottom line
Probiotics may help improve GERD symptoms when used alongside standard treatment.
Recent randomized trials found benefits with specific probiotic formulations, including better symptom control and, in one study, more sustained symptom relief after PPI withdrawal.
However, these findings apply to the specific probiotics that were studied. Evidence for objective improvements such as esophageal healing remains limited, and there is no recommended probiotic strain or dose for GERD.
Current evidence therefore supports probiotics only as a possible adjunct to standard treatment, not as a standalone therapy or replacement for GERD medication.